The Valley Desk

NCT04137900 · Interventional trial

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Overall registry status Unknown

Phase 1

Conditions Advanced Unresectable Solid Tumor, Metastatic Solid Tumor

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov